REFERENCES

1. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and

treatment. Lancet 2006;368(9534):489–504.

2. DeGruttola V, Seage GR 3rd, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male
homosexual partners. J Clin Epidemiol 1989;42(9):849–856.

3. Incorporating HIV prevention into the medical care of persons living with HIV.
Recommendations of CDC, the Health Resources and Services Administration, the National
Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of
America. MMWR Recomm Rep 2003;52(RR-12):1–24.

4. Boily MC, Baggaley RF, Wang L, Masse B, et al. Heterosexual risk of HIV-1 infection per
sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis
2009;9(2):118–129.

5. Wawer MJ, Makumbi F, Kigozi G, Serwadda D, et al. Circumcision in HIV-infected men and its
effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled
trial. Lancet 2009;374(9685):229–237.

6. Rotheram-Borus MJ, Swendeman D, Chovnick G. The past, present, and future of HIV
prevention: integrating behavioral, biomedical, and structural intervention strategies for the
next generation of HIV prevention. Annu Rev Clin Psychol 2009;5:143–167.

7. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, et al. Antiretroviral postexposure prophylaxis
after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United
States: recommendations from the U.S. Department of Health and Human Services. MMWR
Recomm Rep 2005;54(RR-2):1–20.

8. Stramer SL, Glynn SA, Kleinman SH, Strong DM, et al. Detection of HIV-1 and HCV infections
among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med
2004;351(8): 760–768

9. 9. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of viremia with HBV, HCV, HIV, and
HTLV among tissue donors in the United States. N Engl J Med 2004;351(8):751–759.

10. 10. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, et al. Updated U.S. Public Health
Service guidelines for the management of occupational exposures to HIV and
recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005;54(RR-9):1–17.

11. Public Health Services Task Force. Recommendations for Use of Antiretroviral Drugs in
Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal
HIV-1 Transmission in the United States – Living Document; April 29, 2009. http://www.
AIDSinfo.NIH.gov.

12. Shapiro RL, Smeaton L, Lockman S, Thior I, et al. Risk factors for early and late transmission
of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical
trial in Botswana. J Infect Dis 2009;199(3):414–418.

13. Thior I, Lockman S, Smeaton LM, Shapiro RL, et al. Breastfeeding plus infant zidovudine
prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce
mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA
2006;296(7):794–805.
1. Schneider E, Whitmore S, Glynn KM, Dominguez K, et al. Revised surveillance case
definitions for HIV infection among adults, adolescents, and children aged Infectious
Diseases Society of America and the American College of Physicians. Clin Infect Dis
2009;48(10):1335–1344.

2. 17. Aberg JA, Kaplan JE, Libman H, Emmanuel P, et al. Primary care guidelines for the

3. management of persons infected with human immunodeficiency virus: 2009 update by the

4. HIV medicine association of the infectious diseases society of America. Clin Infect Dis

5. 2009;49(5):651–681. 18. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS

6. 2009;4(4):240–246. 19. UNAIDS. 09 AIDS epidemic report; November 2009. http://data.

7. unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf. 20. Robertson DL, Anderson

8. JP, Bradac JA, Carr JK, et al. HIV-1 nomenclature proposal. Science 2000;288(5463):55–56.

9. 21. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, et al. A new human immunodeficiency

10. virus derived from gorillas. Nat Med 2009;15(8):871–872. 22. Kallings LO. The first

11. postmodern pandemic: 25 years of HIV/ AIDS. J Intern Med 2008;263(3):218–243. 23. Panel

12. on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of

13. antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and

14. Human Services. December 1, 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/

15. AdultandAdolescentGL.pdf. 24. Tang H, Kuhen KL, Wong-Staal F. Lentivirus replication and

16. regulation. Annu Rev Genet 1999;33:133–170. 25. Stewart GJ, Ashton LJ, Biti RA, Ffrench

17. RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-

18. progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.

19. AIDS 1997;11(15):1833–1838. 26. Cullen BR. Role and mechanism of action of the APOBEC3

20. family of antiretroviral resistance factors. J Virol 2006;80(3):1067–1076. 27. Neil SJ, Zang T,

21. Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature

22. 2008;451(7177):425–430. 28. Derdeyn CA, Silvestri G. Viral and host factors in the

23. pathogenesis of HIV infection. Curr Opin Immunol 2005;17(4):366–373. 29. Grossman Z,

24. Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus

25. spares is as important as what it destroys. Nat Med 2006;12(3):289–295. 30. Kahn JO,

26. Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med

27. 1998;339:33–39. 31. Mellors JW, Rinaldo CR, Jr, Gupta P, White RM, et al. Prognosis in HIV-1

28. infection predicted by the quantity of virus in plasma. Science 1996;272:1167–1170. 32.

29. Khoury M, Kovacs A. Pediatric HIV infection. Clin Obstet Gynecol 2001;44(2):243–275. 33.
30. Centers for Disease Control and Prevention. 1994 revised classification system for human

31. immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-

32. 12):1–10. 34. Mofenson LM, Brady MT, Danner SP, Dominguez KL, et al. Guidelines for the

33. Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected

34. children: recommendations from CDC, the National Institutes of Health, the HIV Medicine

35. Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases

36. Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009;58(RR-11):1–

37. 166. 35. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected

38. Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February

39. 23, 2009; pp 1-139. http:// aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. 36.

40. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, et al. The survival benefits of AIDS

41. treatment in the United States. J Infect Dis 2006;194(1):11–19. 37. NIH Panel to Define

42. Principles of Therapy of HIV Infection. Report of the NIH panel to define principles of therapy

43. of HIV infection. MMWR 1998;47(RR-5);1–41. 38. Kitahata MM, Gange SJ, Abraham AG,

44. Merriman B, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N

45. Engl J Med 2009;360(18):1815–1826. 39. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S,

46. Kaewkungwal J, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in

47. Thailand. N Engl J Med 2009;361(23):2209–2220.

48. 40. Abrams D, Levy Y, Losso MH, Babiker A, et al. Interleukin-2 therapy in patients with HIV

49. infection. N Engl J Med 2009;361(16): 1548–1559. 41. Hendrix CW, Cao YJ, Fuchs EJ. Topical

50. microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol

51. Toxicol 2009;49:349–375. 42. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular

52. pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and

53. its relationship to clinical toxicities. Clin Infect Dis 2004;38(5):743–753. 43. Anderson MS,

54. Kakuda TN, Hanley W, Miller J, et al. Minimal pharmacokinetic interaction between the

55. human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and

56. the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother

57. 2008;52(12):4228–4232. 44. Calmy A, Hirschel B, Cooper DA, Carr A. A new era of

58. antiretroviral drug toxicity. Antivir Ther 2009;14(2):165–179. 45. Carr A. Toxicity of

59.

60. antiretroviral therapy and implications for drug development. Nat Rev Drug Discov
61.

62. 2003;2:624–634. 46. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, et al.

63.

64. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an

65.

66. International AIDS Society-USA panel. Clin Infect Dis 2008;47(2):266–285. 47. Telenti A.

67. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 2009;4(2):131–135.

68. 48. Xu L, Desai MC. Pharmacokinetic enhancers for HIV drugs. Curr Opin Investig Drugs

69. 2009;10(8):775–786. 49. Stellbrink HJ. Novel compounds for the treatment of HIV type-1

70. infection. Antivir Chem Chemother 2009;19(5):189–200. 50. Romanelli F, Smith KM, Hoven

71. AD. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus

72. (HIV-1) activity. Curr Pharm Des 2004;10(21):2643–2648. 51. McMahon MA, Siliciano JD,

73. Lai J, Liu JO, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the

74. V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008;283(46):31289–

75. 31293. 52. Canestri A, Ghosn J, Wirden M, Marguet F, et al. Foscarnet salvage therapy for

76. patients with late-stage HIV disease and multiple drug resistance. Antivir Ther

77. 2006;11(5):561–566. 53. Kaplan JE, Benson C, Holmes KH, Brooks JT, et al. Guidelines for

78. prevention and treatment of opportunistic infections in HIVinfected adults and

79. adolescents: recommendations from CDC, the National Institutes of Health, and the HIV

80. Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep

81. 2009;58(RR-4):1-207; quiz CE1–4. 54. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, et al.

82. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related

83. complex. N Engl J Med 1987;317:185–191. 55. Hammer SM, Katzenstein DA, Hughes MD,

84. Gundacker H, et al. A trial comparing nucleoside monotherapy with combination therapy in

85. HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med

86. 1996;335:1081–1090. 56. Hammer SM, Squires K, Hughes M, Grimes JM, et al. A controlled

87. trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency

88. virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials

89. Group 320 Study Team. N Engl J Med 1997;337:725–733. 57. Palella FJ, Jr, Delaney KM,

90. Moorman AC, Loveless MO, et al. Declining morbidity and mortality among patients with

91. advanced human immunodeficiency virus infection. N Engl J Med 1998;338: 853–860. 58.
92. Walmsley S, Bernstein B, King M, Arribas J, et al. Lopinavir-ritonavir versus nelfinavir for the

93. initial treatment of HIV infection. N Eng J Med 2002;346:2039–2046. 59. Gulick RM, Ribaudo

94. HJ, Shikuma CM, Lustgarten S, et al. Triplenucleoside regimens versus efavirenz-containing

95. regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18): 1850–1861.

96. 60. World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection in

97. adults and adolescents; November 2009. http://www.

98. who.int/hiv/pub/arv/advice/en/index.html

99. 61. Gardner EM, Burman WJ, Steiner JF, Anderson PL, et al. Antiretroviral CHAPTER 134

100. medication adherence and the development of class-specific antiretroviral resistan

101. ce. AIDS 2009;23(9):1035–1046. 62. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, et
al. Safet

102. y and efficacy of raltegravir-based versus efavirenz-based combination therapy in

treatme

103. nt-naive patients with HIV-1 infection: a multicentre, doubleblind randomised

control

104.

105. ed trial. Lancet 2009;374(9692):796–806. 63. Gallant JE, DeJesus E, Arribas JR,
Pozniak

106. AL, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and
efavirenz

107. z for HIV. N Engl J Med 2006;354(3):251–260. 64. Ortiz R, Dejesus E, Khanlou H,
Voronin

108. E, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir

109. r/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008;22

110. (12): 1389–1397. 65. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P,

et al. On

111. ce-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combina

112. tion with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-
infected

113. patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;37

114. 2(9639):646–655. 66. Sax PE, Tierney C, Collier AC, Fischl MA, et al. Abacavir-lamivud

115. ine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;36

116. 1(23):2230–2240. 67. Ha B, Liao QM, Dix LP, Pappa KA. Virologic response and safety
of the a
117. bacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral
therapy:

118. analyses of six clinical studies. HIV Clin Trials 2009;10(2):65–75. 68. Riddler SA,
Haubric

119. h R, DiRienzo AG, Peeples L, et al. Class-sparing regimens for initial treatment of HIV-
1 infecti

120. on. N Engl J Med 2008;358(20):2095–2106. 69. Bierman WF, van Agtmael MA,
Nijhuis

121. M, Danner SA, et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a
systematic review. AIDS 2009;23(3):279–291. 70. Turner D, Brenner BG, Routy JP, Petrella M,
et al. Ra

122. tionale for maintenance of the M184V resistance mutation in human immune

123. deficiency virus type 1 reverse transcriptase in treatment experienced patients. New
Mi

124. crobiol 2004;27(2 Suppl 1):31–39. 71. McIntyre JA, Hopley M, Moodley D, Eklund M,
et al. Eff

125. icacy of shortcourse AZT plus 3TC to reduce nevirapine resistance in the preven

126. tion of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med
2009;6(

127.

128.

129. 10):e1000172. 72. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, et al. CD4+ count-
guided interruption of antiretroviral treatment. N Engl J Med 2006;355(22):2283–2296. 73.
Phillips

130. AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS
20

131. 08;22(18):2409–2418. 74. Taylor S, Boffito M, Khoo S, Smit E, et al. Stopping antiretr

132.

133. oviral therapy. AIDS 2007;21(13):1673–1682. 75. Beishuizen SJ, Geerlings SE.
Immune

134. reconstitution inflammatory syndrome: immunopathogenesis, risk factors, diagnosi

135. s, treatment and prevention. Neth J Med 2009;67(10):327–331. 76. Zolopa A,

Andersen J, Powderly W, Sanchez A, et al. Early antiretroviral therapy reduces AIDS progress

136. sion/death in individuals with acute opportunistic infections: a multicenter random

137. ized strategy trial. PLoS One 2009;4(5):e5575. 77. Krajicek BJ, Thomas CF, Jr., Limper
AH. Pne
138. umocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment.
Clin Che

139. st Med 2009;30(2):265–278, vi. 78. Santamauro J, Stover D. Pneumocystis carinii

pneumo

140. nia. Med Clin North America 1997;81:299–318. 79. Kovacs JA, Masur H. Evolving
health e

141. ffects of Pneumocystis: one hundred years of progress in diagnosis and treatment.
JAMA 2

142.

143. 009;301(24):2578–2585. 80. Wofsy C. Use of trimethoprim-sulfamethoxazole in the

treatme

144. nt of Pneumocystis carinii pneumonitis in patients with acquired immunodeficiency

syndrome

145. e. Rev Infect Dis 1987;9(Suppl 2):S184-S194. 81. Wharton J, Coleman D, Wofsy C,
Luce JM

146. , et al. Trimethorprimsulfamethoxazole or pentamidine for Pneumocystis carinii

pneumo

147. nia in the acquired immunodeficiency syndrome. Ann Intern Med 1986;105:37–44.
82. Mor

148. se CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of
success.

149.

150.

151.

152. JAMA 2006;296(7):844–854.